Promising Results of Cendakimab to Treat EoE

The findings from a phase 3 clinical trial for a potential treatment called cendakimab were recently released at two medical conferences. Cendakimab is a biologic medicine that targets a protein called interleukin 13. This specific protein is a key mediator of type 2 inflammation and contributes to eosinophil recruitment, epithelial barrier dysfunction, and fibrosis (scarring).

The findings showed that cendakimab reduced symptoms and inflammation in the esophagus for adults and teens with eosinophilic esophagitis (EoE).

Treatment with cendakimab also improved key endoscopic and histologic features, even in those who did not have success with steroid treatment, or an intolerance to steroids.

These results were presented at the United European Gastroenterology (UEG) Week 2024 in October and additionally showed cendakimab to be generally safe and well tolerated through 24 weeks of treatment.

Additional findings from the phase 3 study for cendakimab were also presented in October at the 2024 annual meeting of the American College of Gastroenterology. The findings confirm cendakimab’s efficacy (symptom & inflammation reduction), safety & tolerability through 48 weeks of treatment

Cendakimab is being developed by Bristol-Myers Squibb.